Bilimsel çalışmalar

Doç. Dr. Murat Ayhan

52 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Açık erişimli tam metinKaynak: OpenAlex

  2. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Kaynak: OpenAlex

  3. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  4. Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

    Molecular and Clinical Oncology, 2025

    DOI 10.3892/mco.2025.2846 PMID 40297501 Açık erişimli tam metinKaynak: OpenAlex

  5. Real-World Experience with Non-Metastatic Male Breast Cancer: A 222-Patient Multicenter Study from the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17243895 PMID 41463146 Açık erişimli tam metinKaynak: OpenAlex

  6. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

    Journal of Immunotherapy, 2024

    DOI 10.1097/cji.0000000000000508 PMID 38333962 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  7. Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer

    Future Oncology, 2024

    DOI 10.2217/fon-2023-0763 PMID 38328890 Kaynak: OpenAlex

  8. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 atıf (Europe PMC) Kaynak: OpenAlex

  9. The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study

    International Journal of Cancer, 2023

    DOI 10.1002/ijc.34749 PMID 37818966 21 atıf (Europe PMC) Kaynak: OpenAlex

  10. HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer

    Journal of College of Physicians And Surgeons Pakistan, 2023

    DOI 10.29271/jcpsp.2023.12.1405 PMID 38062597 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens

    Oncology Letters, 2023

    DOI 10.3892/ol.2023.13795 PMID 37123028 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  12. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study

    Cureus, 2023

    DOI 10.7759/cureus.39119 PMID 37216135 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  13. 443P Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.619 Açık erişimli tam metinKaynak: OpenAlex

  14. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

    Expert Review of Anticancer Therapy, 2022

    DOI 10.1080/14737140.2022.2076670 PMID 35543015 3 atıf (Europe PMC) Kaynak: OpenAlex

  15. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  16. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  17. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2073159 PMID 35579894 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  18. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2040770 PMID 35174772 Açık erişimli tam metinKaynak: OpenAlex

  19. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

    Medicine, 2022

    DOI 10.1097/md.0000000000030147 PMID 36107512 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  20. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001310 PMID 35703239 3 atıf (Europe PMC) Kaynak: OpenAlex

  21. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.43076 Kaynak: OpenAlex

  22. Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-89749 Kaynak: OpenAlex

  23. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background

    Annals of Medical Research, 2022

    DOI 10.5455/annalsmedres.2021.07.490 Kaynak: OpenAlex

  24. Gastrointestinal Stromal Tümörler ve Nöroendokrin Tümörlere Yaklaşım

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.2139 Kaynak: OpenAlex

  25. Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0398 PMID 34323116 2 atıf (Europe PMC) Kaynak: OpenAlex

  26. Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group

    Van Yüzüncü Yıl University Academic Data Management System, 2021

    DOI 10.4999/uhod.215190 2 atıf (OpenAlex) Kaynak: OpenAlex

  27. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-021-03748-7 PMID 34331582 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  28. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

    Melanoma Research, 2021

    DOI 10.1097/cmr.0000000000000744 PMID 34039945 16 atıf (Europe PMC) Kaynak: OpenAlex

  29. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center’s experience

    Journal of Chemotherapy, 2021

    DOI 10.1080/1120009x.2021.1923153 PMID 34032198 6 atıf (Europe PMC) Kaynak: OpenAlex

  30. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211015762 PMID 33961521 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-020-03501-6 PMID 33433657 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

    Tumori Journal, 2021

    DOI 10.1177/03008916211037739 PMID 34365852 5 atıf (Europe PMC) Kaynak: OpenAlex

  33. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211050084 PMID 34846181 1 atıf (Europe PMC) Kaynak: OpenAlex

  34. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin

    Journal of College of Physicians And Surgeons Pakistan, 2021

    DOI 10.29271/jcpsp.2021.11.1308 PMID 34689488 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2021-84414 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  36. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211038136 PMID 34558355 1 atıf (Europe PMC) Kaynak: OpenAlex

  37. Küçük Molekül Tirozin Kinaz İnhibitörleri; ROS-1 Hedefli Tedaviler (Krizotinib, Seritinib)

    2021

    Kaynak: OpenAlex

  38. 1076P Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group study

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1461 Kaynak: OpenAlex

  39. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?

    Current Problems in Cancer, 2020

    DOI 10.1016/j.currproblcancer.2020.100670 PMID 33129567 1 atıf (Europe PMC) Kaynak: OpenAlex

  40. Outcome of non-metastatic male breast cancer: 222 patients

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz240.024 Açık erişimli tam metinKaynak: OpenAlex

  41. Daha Önce Tedavi Almıs, Östrojen Reseptörü Pozitif, HER2-Negatif, Lokal Ileri Evre veya Metastatik Meme Kanseri Hastalarında GDC-9545 iIe Hekimin Tercih Ettigi Endokrin Monoterapinin Etkililigi ve Güvenliliginin Karsılastırmalı Olarak Degerlendirildigi Faz II, Randomize, Açık Etiketli, Çok Merkezli Çalısma, Diger (Uluslararası), Dr. Murat Ayhan

    Kaynak: livhospital.com profil sayfası

  42. Pık3ca-Mutant, Hormon Reseptör-Pozitif, HER2-Negatif, Lokal Ileri Ya da Metastatik Meme Kanseri Olan Hastalarda Gdc-0077 Ile Birlikte Palbocıclıb Ve Fulvestrant’a Kıyasla Plasebo Ile Birlikte Palbocıclıb ve Fulvestrant’ın Etkililik ve Güvenliligini Degerlendiren Faz III, Randomize, Çift Kör, Plasebo Kontrollü Çalısma , Diger (Uluslararası), Dr. Murat Ayhan

    Kaynak: livhospital.com profil sayfası

  43. Daha Önce Tedavi Edilmis Lokal Ileri veya Metastatik Küçük Hücreli Dısı Akciger Kanseri Olan Hastalarda Intravenöz Atezolizumaba Kıyasla Subkutan Atezolizumabın Farmakokinetigi, Etkililigi ve Güvenliliginin Degerlendirildigi Randomize, Çok Merkezli, Faz Ib/III Çalısma, Diger (Uluslararası) Dr. Murat Ayhan

    Kaynak: livhospital.com profil sayfası

  44. PSMA-PET-Pozitif Yüksek Riskli Hormona Duyarlı Prostat Kanserli Hastalarda Radyoterapi ve LHRH Agonistine Apalutamid Eklenmesinin Etkililik ve Güvenilirliginin Arastırıldıgı, PSMA-PET-Negatif Hastalar için Gözlem Takibi Içeren Randomize, Kontrollü, Çok Merkezli, Açık Etiketli Çalısma , Diger (Uluslararası) Dr. Murat Ayhan

    Kaynak: livhospital.com profil sayfası

  45. Ileri Evre Ürotelyal Kanseri ve Fibroblast Büyüme Faktörü Reseptörü Gen Aberasyonları olan Hastaları Belirlemeye Yönelik Biyobelirteç Çalısması-42756493BLC0002, Diger (Uluslararası), Dr. Murat Ayhan

    Kaynak: livhospital.com profil sayfası

  46. Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitisation With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.

    Kaynak: livhospital.com profil sayfası

  47. Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.

    Kaynak: livhospital.com profil sayfası

  48. Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30

    Kaynak: livhospital.com profil sayfası

  49. Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.

    Kaynak: livhospital.com profil sayfası

  50. Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720

    Kaynak: livhospital.com profil sayfası